MCID: LMB062
MIFTS: 55

Limb Ischemia

Categories: Cardiovascular diseases

Aliases & Classifications for Limb Ischemia

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia 12 15 37 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050852
UMLS 71 C2945695

Summaries for Limb Ischemia

Disease Ontology : 12 An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary : Limb Ischemia is related to peripheral vascular disease and ischemia. An important gene associated with Limb Ischemia is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Aspirin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are cardiovascular system and cellular

Related Diseases for Limb Ischemia

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 31.6 VWF VEGFA SELE IL6 F2 CCL2
2 ischemia 31.5 VEGFA TEK SELE NOS3 MIR21 KDR
3 compartment syndrome 31.4 TNF IL6 F2
4 arteriosclerosis obliterans 31.4 MIR21 IL6 HGF
5 end stage renal disease 31.2 VEGFA TNF NOS3 IL6 CCL2 ACE
6 cardiogenic shock 31.1 TNF IL6
7 congestive heart failure 31.1 VEGFA TNF NOS3 IL6 ACE
8 arteries, anomalies of 30.9 VEGFA TNF NOS3 MIR21 IL6 CCL2
9 aortic aneurysm, familial abdominal, 1 30.9 TNF NOS3 IL6 CCL2 ACE
10 osteomyelitis 30.9 TNF IL6 CCL2
11 severe acute respiratory syndrome 30.9 TNF IL6 CCL2 ACE
12 endocarditis 30.9 TNF IL6 F2
13 peripheral artery disease 30.9 VWF VEGFA TNF NOS3 IL6 HIF1A
14 vasculitis 30.9 VWF TNF SELE IL6 CCL2
15 antiphospholipid syndrome 30.8 VWF TNF SELE F2
16 lipid metabolism disorder 30.8 SELE IL6 CCL2 ACE
17 intermittent claudication 30.7 VWF VEGFA TEK PGF IL6 F2
18 polyarteritis nodosa 30.7 SELE IL6 FGF2
19 systemic scleroderma 30.7 TNF SELE IL6 ACE
20 disseminated intravascular coagulation 30.6 VWF TNF IL6 F2
21 proteasome-associated autoinflammatory syndrome 1 30.6 TNF SELE IL6 CCL2
22 cerebrovascular disease 30.6 VWF TNF SELE MIR21 IL6 F2
23 chronic ulcer of skin 30.6 VEGFA TNF IL6 FGF2
24 cellulitis 30.5 TNF IL6 F2
25 homocysteinemia 30.5 VWF NOS3 F2 CCL2
26 respiratory failure 30.5 VEGFA TNF IL6 F2 CCL2 ANGPT2
27 chronic kidney disease 30.4 VEGFA TNF SELE NOS3 MIR21 IL6
28 pulmonary edema 30.4 TNF TEK NOS3 HIF1A F2 ACE
29 vascular disease 30.4 VWF VEGFA TNF SELE NOS3 MIR21
30 angina pectoris 30.4 NOS3 IL6 ACE
31 hyperglycemia 30.4 SELE NOS3 IL6 HIF1A
32 arteriosclerosis 30.4 SELE NOS3 MIR21 IL6 HIF1A HGF
33 atherosclerosis susceptibility 30.4 VWF VEGFA TNF SELE NOS3 IL6
34 soft tissue sarcoma 30.4 VEGFA TNF HIF1A
35 thrombocytosis 30.3 VWF IL6 F2
36 kidney disease 30.3 VEGFA TNF NOS3 MIR21 IL6 HGF
37 pneumonia 30.3 TNF IL6 F2 CCL2 ACE
38 purpura 30.3 VWF TNF IL6 F2 ACE
39 essential thrombocythemia 30.3 VWF VEGFA TNF IL6 FGF2 F2
40 acute myocardial infarction 30.3 VWF SELE MIR21 IL6 ACE
41 uremia 30.3 VWF TNF IL6 ACE
42 peripartum cardiomyopathy 30.3 VEGFA PGF MIR21 ACE
43 infective endocarditis 30.3 TNF IL6 F2
44 decubitus ulcer 30.2 VEGFA TNF IL6 FGF2
45 sarcoma 30.2 VEGFA KDR IL6 HIF1A FGF2 ANGPT2
46 localized scleroderma 30.2 TNF SELE IL6
47 adult respiratory distress syndrome 30.2 TNF SELE IL6 F2 ANGPT2 ACE
48 plague 30.2 TNF SELE IL6
49 exanthem 30.2 VEGFA TNF IL6 F2 ACE
50 acute cystitis 30.2 TNF IL6 F2 CCL2 ACE

Graphical network of the top 20 diseases related to Limb Ischemia:



Diseases related to Limb Ischemia

Symptoms & Phenotypes for Limb Ischemia

MGI Mouse Phenotypes related to Limb Ischemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 ACE ANGPT2 CXCL12 F2 FGF2 HGF
2 cellular MP:0005384 10.35 ANGPT2 CXCL12 F2 FGF2 HGF HIF1A
3 hematopoietic system MP:0005397 10.34 ACE ANGPT2 CXCL12 FGF2 HGF HIF1A
4 homeostasis/metabolism MP:0005376 10.32 ACE ANGPT2 F2 FGF2 HIF1A IL6
5 immune system MP:0005387 10.3 ACE ANGPT2 CCL2 CXCL12 F2 HIF1A
6 mortality/aging MP:0010768 10.24 ACE ANGPT2 CXCL12 F2 FGF2 HGF
7 embryo MP:0005380 10.16 ACE F2 HGF HIF1A KDR PGF
8 digestive/alimentary MP:0005381 10.13 ANGPT2 F2 HIF1A IL6 NOS3 TNF
9 integument MP:0010771 10.13 ANGPT2 F2 HIF1A IL6 KDR PGF
10 liver/biliary system MP:0005370 10.1 ACE CXCL12 HGF HIF1A IL6 KDR
11 muscle MP:0005369 10.02 CXCL12 F2 FGF2 HIF1A IL6 KDR
12 nervous system MP:0003631 9.97 ACE CXCL12 F2 FGF2 HGF HIF1A
13 neoplasm MP:0002006 9.8 ACE FGF2 HIF1A IL6 PGF TNF
14 respiratory system MP:0005388 9.65 ANGPT2 F2 HIF1A IL6 KDR NOS3
15 vision/eye MP:0005391 9.4 ACE ANGPT2 FGF2 HIF1A IL6 KDR

Drugs & Therapeutics for Limb Ischemia

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Evolocumab Approved Phase 4 1256937-27-5
4
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
5
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
6 Pharmaceutical Solutions Phase 4
7 Analgesics, Non-Narcotic Phase 4
8 Cyclooxygenase Inhibitors Phase 4
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Antirheumatic Agents Phase 4
11 Antipyretics Phase 4
12 Antimetabolites Phase 4
13 Hypolipidemic Agents Phase 4
14 Lipid Regulating Agents Phase 4
15 Anticholesteremic Agents Phase 4
16 Protective Agents Phase 4
17 Respiratory System Agents Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Phosphodiesterase Inhibitors Phase 4
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Neuroprotective Agents Phase 4
22 Bronchodilator Agents Phase 4
23 Vasodilator Agents Phase 4
24 Analgesics Phase 4
25 Anticonvulsants Phase 4
26 Psychotropic Drugs Phase 4
27 Hormones Phase 4
28 Calcium, Dietary Phase 4
29 Anti-Anxiety Agents Phase 4
30 calcium channel blockers Phase 4
31
Calcium Nutraceutical Phase 4 7440-70-2 271
32
Caffeine Approved Phase 3 58-08-2 2519
33
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
34
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
35
Pentetic acid Approved Phase 3 67-43-6
36
Procaine Approved, Investigational, Vet_approved Phase 3 59-46-1 4914
37
Iron Approved Phase 3 7439-89-6 23925 29936
38
Apixaban Approved Phase 3 503612-47-3 10182969
39
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
40
Clopidogrel Approved Phase 2, Phase 3 120202-66-6, 113665-84-2 60606
41
Treprostinil Approved, Investigational Phase 3 81846-19-7 54786 6918140
42
Ticagrelor Approved Phase 2, Phase 3 274693-27-5 9871419
43
Pantothenic acid Approved, Nutraceutical, Vet_approved Phase 3 79-83-4 6613
44
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
45
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 70-16-6, 59-43-8 1130
46 Anesthetics Phase 3
47 Calamus Phase 3
48 calcium heparin Phase 3
49 Anticoagulants Phase 3
50 Vitamin B 6 Phase 3

Interventional clinical trials:

(show top 50) (show all 307)
# Name Status NCT ID Phase Drugs
1 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
2 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
3 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
4 CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5). Completed NCT00459888 Phase 4
5 Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study Completed NCT01558505 Phase 4
6 International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease Completed NCT02369809 Phase 4 Neovasculgen®
7 Effect of Combined Remote Ischemic Preconditioning and Postconditioning on Acute Pulmonary Injury in Patients Undergoing Valvular Heart Surgery Completed NCT01427621 Phase 4
8 Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV) Completed NCT00596752 Phase 4 Alprostadil
9 Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Completed NCT02563535 Phase 4
10 Effect of Evolocumab in Patients With Critical Limb Ischemia Recruiting NCT04306471 Phase 4 Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
11 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Recruiting NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
12 Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia. Not yet recruiting NCT04312555 Phase 4 Alprostadil
13 Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study Terminated NCT00403780 Phase 4 pregabalin;placebo
14 Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia Terminated NCT00504088 Phase 4
15 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Withdrawn NCT02408991 Phase 4 Neupogen
16 The Impact of Repeated Bilateral Limb Remote Ischemic Conditioning on Patients With Chronic Cerebral Ischemia: Establishment of Optimized Algorithm on the Basis of Feasibility, Safety and Efficacy Unknown status NCT03105141 Phase 2, Phase 3
17 Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients Unknown status NCT02538978 Phase 3
18 Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb Unknown status NCT01211925 Phase 2, Phase 3 Aspirin
19 An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia Unknown status NCT02856230 Phase 2, Phase 3
20 Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG) Unknown status NCT01818310 Phase 2, Phase 3
21 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
22 Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia Unknown status NCT02820467 Phase 3
23 Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease Completed NCT01245335 Phase 3
24 Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells Completed NCT01833585 Phase 3
25 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization Completed NCT01483898 Phase 3
26 Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells Completed NCT02454231 Phase 2, Phase 3
27 Remote Ischemic Preconditioning in High Risk Cardiovascular Surgery Patients: A Randomized Controlled Trial Completed NCT01328912 Phase 3
28 Clinical and Genomic Responses to Open Heart Surgery: A Randomized Controlled Trial of the Effects of Remote Ischemic Preconditioning Completed NCT00650507 Phase 3
29 A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions Completed NCT00566657 Phase 3
30 Cell Therapy in Critical Limb Ischemia Completed NCT00904501 Phase 3
31 A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia Recruiting NCT03551496 Phase 3
32 Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study Recruiting NCT01450722 Phase 3
33 Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI) Recruiting NCT03423732 Phase 2, Phase 3 CardioCell;Placebos
34 Trial to Assess Chelation Therapy in Critical Limb Ischemia Recruiting NCT03982693 Phase 3 Edetate Disodium
35 Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb Recruiting NCT04229264 Phase 3 Apixaban;ASA;Clopidogrel 75mg
36 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Recruiting NCT03111238 Phase 3 REX-001;Placebo
37 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 5) Recruiting NCT04274049 Phase 3
38 The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial Recruiting NCT03174522 Phase 3 REX-001;Placebo
39 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4) Recruiting NCT04275323 Phase 3
40 Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization Active, not recruiting NCT03006770 Phase 3
41 Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia Active, not recruiting NCT00471289 Phase 2, Phase 3
42 A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia Terminated NCT02144610 Phase 3
43 A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures Terminated NCT00060996 Phase 3 Remodulin® (treprostinil sodium) Injection
44 Remote Ischaemic Preconditioning for Heart Surgery Terminated NCT01067703 Phase 3
45 A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft Terminated NCT00067041 Phase 2, Phase 3 Remodulin (treprostinil sodium) Injection
46 A Physician Initiated Prospective Multicenter Study on Excimer Laser Recanalisation in the Treatment of Long Infrapopliteal Lesions in Patients With Critical Limb Ischemia Terminated NCT00718991 Phase 2, Phase 3
47 Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase Terminated NCT01638585 Phase 3 urokinase
48 Low Dose Urokinase Therapy in Patients With Diabetic Foot Syndrome and Critical Limb Ischemia Versus Conventional Standard Therapy Terminated NCT00823225 Phase 3 Urokinase
49 Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia Terminated NCT02230527 Phase 2, Phase 3 Ticagrelor;Clopidogrel
50 Single Blind Randomized Controlled Crossover Trial of the Effects of Remote Preconditioning on the Tissue Metabolism During Exercise and Ischemia Unknown status NCT00791206 Phase 2

Search NIH Clinical Center for Limb Ischemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Limb Ischemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Limb Ischemia:
ACP-01, autologous angiogenic precursor cells for critical limb ischemia
ACT34-CLI, bone marrow-derived cells for critical limb ischemia
ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
ALD-301, bone marrow-derived cells for critical limb ischemia
Alecmestencel-T, mesenchymal stem cells for ischemic diseases
ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
Autologous CD133+ cells for treatment of critical limb ischemia
Autologous endothelial progenitor cells for the treatment of critical limb ischemia
Autologus endothelial progenitor cells for the treatment of critical limb ischemia
Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
Bone marrow-derived mononuclear cells for critical limb ischemia
Bone marrow-derived mononuclear cells for peripheral vascular disease
Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
Bone marrow-derived stem cells for treatment of diabetic foot ulcers
Enriched bone marrow-derived progenitor cells for ischemic diseases
ERCs, endometrial regenerative cells for critical limb ischemia
Hematopoietic stem cells for limb ischemia and diabetic neuropathy
itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
Mesendo, stem cell combination for treatment of limb ischemia
MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
PDA002, Placenta-derived cells for vascular disease
Peripheral blood-derived hematopoietic stem cells for leg gangrene
PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
ReN009, human neural stem cells for peripheral arterial disease
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
StempeucelCLI, mesenchymal stem cells for vascular diseases
Umbilical cord blood stem cells for treatment of critical limb ischemia
Embryonic/Adult Cultured Cells Related to Limb Ischemia:
Angiogenic cell precursors
Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 23192920 9020076 22163120
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
Bone marrow-derived mesenchymal stem cells (family)
Cord blood-derived hematopoietic stem cell PMIDs: 19558779
Bone marrow-derived mononuclear cells (family) PMIDs: 17394441 23586040 21216483
Peripheral blood-derived endothelial progenitor cells (family)
Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 18351022 19896796 19500466 22019148
Bone marrow-derived mononuclear cells
Bone marrow-derived mononuclear cells
Tissue repair cells PMIDs: 17394441 23586040
Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
Bone marrow-derived progenitor cells
Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
Bone marrow-derived mononuclear cells PMIDs: 21586448
Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
MultiGeneAngio, transduced vein-derived endothelial cells
Genetically modified vein-derived endothelial cells
MultiGeneAngio, transduced vein-derived smooth muscle cells
Genetically modified vein-derived smooth muscle
Placenta-derived cells
Peripheral blood-derived hematopoietic stem cells
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
Neural stem cell line (CTX0E03) PMIDs: 23067568
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 23307180 18720444 22731756
Umbilical cord blood-derived hematopoietic stem cells (family)

Genetic Tests for Limb Ischemia

Anatomical Context for Limb Ischemia

MalaCards organs/tissues related to Limb Ischemia:

40
Bone Marrow, Endothelial, Bone, Skeletal Muscle, Heart, Placenta, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Limb Ischemia:
# Tissue Anatomical CompartmentCell Relevance
1 Limb Pelvic Girdle Bone Marrow Stromal Cells Potential therapeutic candidate
2 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
3 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
4 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Limb Ischemia

Articles related to Limb Ischemia:

(show top 50) (show all 7697)
# Title Authors PMID Year
1
Nerve growth factor in muscle afferent neurons of peripheral artery disease and autonomic function. 61
33063730 2021
2
Evolution of Major Amputation Risk in Patients Hospitalized in France for Critical Limb Ischemia: The COPART Registry. 61
33267644 2021
3
Ultrasound-Mediated Microbubble Cavitation Transiently Reverses Acute Hindlimb Tissue Ischemia through Augmentation of Microcirculation Perfusion via the eNOS/NO Pathway. 61
33487472 2021
4
The Monocyte/High Density Lipoprotein Cholesterol Ratio (MHR) as an Indicator of the Need for Amputation in Patients With Peripheral Artery Disease Developing Critical Limb Ischemia. 61
33108889 2021
5
A Retrospective Comparative Study of Twelve-Month Clinical Outcomes for Drug-Coating Balloon Angioplasty and Stent Implantation in Treating Patients with Popliteal Obstructive Lesions. 61
33249531 2021
6
Early venoarterial extracorporeal membrane oxygenation improves outcomes in post-cardiotomy shock. 61
32926268 2021
7
Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy. 61
32914347 2021
8
The One Hundred Most Cited Articles in the Diagnosis and Management of Peripheral Artery Disease. 61
33592290 2021
9
Optimal cut-off value of preprocedural geriatric nutritional risk index for predicting the clinical outcomes of patients undergoing endovascular revascularization for peripheral artery disease. 61
32888832 2021
10
Association of the Prognosis of Ankle-brachial Index Improvement One Year Following Endovascular Therapy in Patients with Peripheral Artery Disease: Data from the I-PAD NAGANO Registry. 61
33518563 2021
11
Impact of Gender Differences on Outcomes of Peripheral Artery Disease Intervention (from a Nationwide Sample). 61
33217346 2021
12
Acute Thrombosis of an Infrarenal Abdominal Aortic Aneurysm Presenting as Bilateral Critical Lower Limb Ischemia. 61
32909901 2021
13
Characteristics and clinical indicators of concomitant venous thromboembolism in acute limb ischemia. 61
33140627 2021
14
Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients with COVID-19: the PREVENT-HD Study. 61
33577800 2021
15
COVID-19 and Its Implications for Thrombosis and Anticoagulation. 61
33548929 2021
16
Remote ischemic conditioning avoids the development of intestinal damage after ischemia reperfusion by reducing intestinal inflammation and increasing intestinal regeneration. 61
33555396 2021
17
Calcifying characteristics of peripheral vascular smooth muscle cells of chronic kidney disease patients with critical limb ischemia. 61
33591894 2021
18
Endovascular Treatment of Critical Limb Ischemia in Buerger Disease (Thromboangiitis Obliterans) With Midterm Follow-Up: A Viable Option When Bypass Surgery Is Not Feasible. 61
33325735 2021
19
Antegrade and retrograde in-stent tibial artery chronic total occlusion recanalization with double kiss crush (DK crush) stenting of previous stent. 61
33527695 2021
20
Sarcopenia as a prognostic factor in peripheral arterial disease: descriptive review. 61
33556522 2021
21
Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous Bone Marrow-Derived Stem Cells in Patients with Severe Peripheral Arterial Disease. 61
33248918 2021
22
A Case of Critical Essential Thrombocythemia Complicated by Severe Lower-Extremity Arterial Disease. 61
33550325 2021
23
Anterograde and Retrograde Approach With Through-and-Through Wiring Technique to Treat a Ruptured and Extremely Tortuous Giant Popoliteal Artery Aneurism. 61
33568001 2021
24
Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data Registry. 61
33541543 2021
25
Endothelium-Specific GTP Cyclohydrolase I Overexpression Restores Endothelial Function in Aged Mice. 61
33556943 2021
26
Morphologic Characteristics and Endovascular Management of Acute Type B Dissection Patients with Superior Mesenteric Artery Involvement. 61
33548440 2021
27
Comparative performance analysis of interventional devices for the treatment of ischemic disease in below-the-knee lesions: a systematic review and meta-analysis. 61
33547627 2021
28
Acute external iliac artery thrombosis following pelvic fractures: Two case reports. 61
33578610 2021
29
COVID-19 impact on vascular surgery practice: experience from an Italian university regional hub center for vascular pathology. 61
33549797 2021
30
Safety and Efficacy Outcomes of the Pioneer Plus Catheter in Endovascular Revascularization of Lower Extremity Chronic Total Occlusions. 61
33592298 2021
31
Ultrafiltration and Injection of Islet Regenerative Stimuli Secreted by Pancreatic Mesenchymal Stromal Cells. 61
33403929 2021
32
Impact of COVID-19 on the Society for Vascular Surgery Vascular Quality Initiative Arterial Procedure Registry. 61
33548419 2021
33
Early vascular surgery response to the COVID-19 pandemic: Results of a nationwide survey. 61
32454233 2021
34
Use of heparin-bonded expanded polytetrafluoroethylene grafts for renal artery reconstruction. 61
33548401 2021
35
Acute vascular complications of femoral veno-arterial ECMO: a single-centre retrospective study. 61
33606143 2021
36
Pediatric arterial femoral cannulations for extracorporeal membrane oxygenation: Does size really matter? 61
33583565 2021
37
On-pump coronary artery bypass with concomitant descending thoracic aorta-bi-iliac bypass: A case report. 61
33586158 2021
38
A systematic review of brachial artery ligation as a safe and feasible option in the management of arteriovenous dialysis access infection. 61
33548433 2021
39
Telemedicine platforms and their use in the coronavirus disease-19 era to deliver comprehensive vascular care. 61
32622075 2021
40
Endothelial specific deletion of HMGB1 increases blood pressure and retards ischemia recovery through eNOS and ROS pathway in mice. 61
33582562 2021
41
Paclitaxel-Coated Balloon Angioplasty for the Treatment of Infrainguinal Arteries: 24-Month Outcomes in the Full Cohort of BIOLUX P-III Global Registry. 61
33083853 2021
42
Targeted Delivery of a Matrix Metalloproteinases-2 Specific Inhibitor Using Multifunctional Nanogels to Attenuate Ischemic Skeletal Muscle Degeneration and Promote Revascularization. 61
33506676 2021
43
Medical therapy for cardiovascular and limb-related risk reduction in critical limb ischemia. 61
33587692 2021
44
Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia: An Analysis From the National Inpatient Sample Database. 61
33541110 2021
45
A 47-Year Old Woman With Rapidly Progressive Hypoxemic Respiratory Failure. 61
33563457 2021
46
Presentation with perforation of the terminal ileum and acute limb ischemia in Crohn's disease: A case report. 61
33601328 2021
47
Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. 61
32891809 2021
48
Retrograde Pedal Access via Occluded Arteries in Endovascular Treatment of Critical Limb Ischemia. 61
33248916 2021
49
Navigating between the science and art of acute limb ischemia treatment. 61
33587961 2021
50
Ergotism with acute limb ischemia, provoked by HIV protease inhibitors interaction with ergotamine, rescued by multisite transluminal balloon angioplasty. 61
33546816 2021

Variations for Limb Ischemia

Expression for Limb Ischemia

Search GEO for disease gene expression data for Limb Ischemia.

Pathways for Limb Ischemia

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 VWF VEGFA TNF TEK PGF NOS3
2
Show member pathways
14.07 VWF VEGFA TNF TEK SIGLEC5 NOS3
3
Show member pathways
13.87 VEGFA TNF TEK PGF KDR IL6
4
Show member pathways
13.74 VEGFA TEK PGF NOS3 KDR IL6
5
Show member pathways
13.71 TNF TEK NOS3 KDR IL6 HGF
6
Show member pathways
13.59 TEK PGF NOS3 KDR IL6 HGF
7
Show member pathways
13.54 VEGFA TNF TEK PGF KDR IL6
8
Show member pathways
13.45 TNF TEK PGF NOS3 KDR IL6
9
Show member pathways
13.41 VWF VEGFA TNF TEK IL6 HIF1A
10
Show member pathways
13.36 TNF TEK PGF KDR IL6 HGF
11
Show member pathways
13.35 TEK PGF KDR IL6 HGF FGF2
12
Show member pathways
13.35 VWF VEGFA TEK SELE NOS3 HGF
13
Show member pathways
13.32 VEGFA TNF TEK PGF NOS3 KDR
14
Show member pathways
13.1 PGF KDR IL6 HGF FGF2 CXCL12
15
Show member pathways
13.01 VEGFA TNF IL6 HIF1A FGF2 CXCL12
16
Show member pathways
12.95 PGF KDR IL6 HIF1A HGF FGF2
17 12.91 VEGFA PGF IL6 HIF1A HGF FGF2
18
Show member pathways
12.82 VEGFA TEK PGF KDR HGF FGF2
19 12.82 VEGFA TNF TEK PGF KDR HGF
20
Show member pathways
12.78 TNF PGF KDR IL6 HGF FGF2
21
Show member pathways
12.73 VWF VEGFA TNF TEK PGF NOS3
22
Show member pathways
12.7 VEGFA NOS3 KDR CXCL12 CCL2
23
Show member pathways
12.69 VEGFA KDR IL6 HIF1A HGF FGF2
24
Show member pathways
12.57 TNF TEK NOS3 IL6 FGF2 F2
25
Show member pathways
12.47 TEK PGF KDR IL6 HGF FGF2
26
Show member pathways
12.45 VEGFA SELE NOS3 KDR CCL2
27 12.44 VEGFA NOS3 KDR HGF FGF2
28
Show member pathways
12.36 TNF IL6 CXCL12 CCL2
29
Show member pathways
12.36 TNF IL6 F2 CCL2
30
Show member pathways
12.35 TNF PGF KDR IL6 HGF FGF2
31 12.33 VEGFA TNF MIR21 KDR HIF1A HGF
32
Show member pathways
12.27 TEK SELE F2 ANGPT2
33 12.21 VEGFA TNF IL6 HIF1A
34 12.16 TEK KDR FGF2 ANGPT2
35 12.16 VEGFA KDR IL6 HGF FGF2
36 12.16 VEGFA TNF SELE NOS3 KDR CCL2
37 12.03 TNF SELE IL6 CCL2
38 12.01 VEGFA TEK NOS3 IL6 HIF1A ANGPT2
39
Show member pathways
11.97 VEGFA PGF NOS3 KDR HIF1A
40 11.93 VEGFA TNF SELE NOS3 IL6 CCL2
41 11.86 VEGFA TNF IL6 HIF1A HGF FGF2
42 11.85 VEGFA TNF TEK IL6 CXCL12 CCL2
43 11.78 PGF IL6 HGF FGF2 CXCL12
44 11.76 TNF IL6 HGF FGF2 CCL2
45
Show member pathways
11.75 VEGFA TNF SELE IL6
46 11.71 VEGFA HIF1A CXCL12
47 11.63 VEGFA NOS3 HIF1A
48 11.62 VEGFA IL6 HGF FGF2
49 11.61 TNF SELE IL6 HGF CCL2
50 11.6 VEGFA IL6 HIF1A

GO Terms for Limb Ischemia

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VWF VEGFA TNF TEK PGF KDR
2 extracellular space GO:0005615 9.47 VWF VEGFA TNF SELE PGF MIR21
3 platelet alpha granule lumen GO:0031093 9.33 VWF VEGFA HGF

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 VEGFA TEK PGF IL6 HIF1A FGF2
2 multicellular organism development GO:0007275 10.25 VEGFA TNF TEK PGF KDR FGF2
3 negative regulation of apoptotic process GO:0043066 10.14 VEGFA TEK MIR21 KDR IL6 HIF1A
4 positive regulation of gene expression GO:0010628 10.12 VEGFA TNF NOS3 MIR21 IL6 HIF1A
5 positive regulation of cell proliferation GO:0008284 10.11 VEGFA PGF MIR21 KDR IL6 FGF2
6 MAPK cascade GO:0000165 10.05 TNF TEK HGF FGF2 CCL2
7 positive regulation of cell migration GO:0030335 10.05 VEGFA MIR21 KDR HGF CXCL12
8 leukocyte migration GO:0050900 10.02 TNF TEK SELE F2 ANGPT2
9 negative regulation of gene expression GO:0010629 10.02 VEGFA TNF MIR21 KDR HIF1A FGF2
10 cellular response to lipopolysaccharide GO:0071222 10.01 TNF MIR21 IL6 CCL2
11 positive regulation of protein kinase B signaling GO:0051897 10 VEGFA TNF TEK MIR21 HGF FGF2
12 regulation of cell shape GO:0008360 9.98 VEGFA MIR21 KDR F2 CCL2
13 cytokine-mediated signaling pathway GO:0019221 9.98 VEGFA TNF IL6 HIF1A HGF FGF2
14 negative regulation of angiogenesis GO:0016525 9.97 TEK MIR503 MIR21 ANGPT2
15 response to hypoxia GO:0001666 9.97 VEGFA TEK PGF HIF1A CXCL12 ANGPT2
16 positive regulation of MAPK cascade GO:0043410 9.95 VEGFA TEK KDR IL6 FGF2
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 VEGFA TNF IL6
18 angiogenesis GO:0001525 9.92 VEGFA TEK PGF KDR HIF1A FGF2
19 positive regulation of osteoblast differentiation GO:0045669 9.91 MIR21 IL6 HGF
20 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.91 VEGFA TNF HGF
21 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.91 VEGFA PGF KDR
22 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 VEGFA TNF TEK MIR21 KDR FGF2
23 positive regulation of MAP kinase activity GO:0043406 9.9 VEGFA TNF FGF2
24 humoral immune response GO:0006959 9.9 TNF IL6 CCL2
25 positive regulation of cell adhesion GO:0045785 9.89 VEGFA TNF CXCL12
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.89 TNF MIR21 FGF2
27 positive regulation of cell division GO:0051781 9.88 VEGFA PGF FGF2
28 animal organ regeneration GO:0031100 9.88 HGF CXCL12 ANGPT2
29 cellular response to virus GO:0098586 9.87 MIR21 IL6 HIF1A
30 positive chemotaxis GO:0050918 9.87 VEGFA PGF HGF FGF2
31 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.86 TNF HIF1A FGF2
32 negative regulation of endothelial cell proliferation GO:0001937 9.86 TNF MIR503 MIR21
33 negative regulation of blood vessel endothelial cell migration GO:0043537 9.86 TNF MIR503 FGF2 ANGPT2
34 protein kinase B signaling GO:0043491 9.85 TNF KDR CCL2
35 positive regulation of chemokine production GO:0032722 9.85 TNF IL6 HIF1A
36 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.85 VEGFA KDR FGF2
37 positive regulation of endothelial cell migration GO:0010595 9.85 VEGFA TEK MIR21 KDR FGF2
38 positive regulation of JAK-STAT cascade GO:0046427 9.84 TNF IL6 F2
39 sprouting angiogenesis GO:0002040 9.83 VEGFA TEK PGF
40 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TNF MIR21 IL6
41 positive regulation of focal adhesion assembly GO:0051894 9.81 VEGFA TEK KDR
42 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.81 VEGFA MIR503 MIR21
43 positive regulation of protein phosphorylation GO:0001934 9.81 VEGFA TNF TEK PGF MIR21 KDR
44 cell migration involved in sprouting angiogenesis GO:0002042 9.8 VEGFA KDR FGF2
45 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFA NOS3 KDR HIF1A FGF2
46 positive regulation of endothelial cell proliferation GO:0001938 9.8 VEGFA TEK PGF KDR HIF1A FGF2
47 vascular endothelial growth factor signaling pathway GO:0038084 9.79 VEGFA PGF KDR
48 positive regulation of DNA biosynthetic process GO:2000573 9.79 VEGFA HGF FGF2
49 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.78 TNF MIR21 IL6
50 induction of positive chemotaxis GO:0050930 9.77 VEGFA PGF CXCL12

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.63 VEGFA TNF IL6 FGF2 CXCL12 CCL2
2 heparin binding GO:0008201 9.62 VEGFA PGF FGF2 F2
3 integrin binding GO:0005178 9.56 VWF KDR FGF2 CXCL12
4 vascular endothelial growth factor receptor binding GO:0005172 9.37 VEGFA PGF
5 chemoattractant activity GO:0042056 9.26 VEGFA PGF HGF FGF2
6 growth factor activity GO:0008083 9.17 VEGFA PGF IL6 HGF FGF2 F2

Sources for Limb Ischemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....